GlobeNewswire Inc | Oct 22, 2021 09:00AM EDT

October 22, 2021

NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc.(NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2021 financial results and provide a business update onTuesday, November 2, 2021, prior to the open of the U.S. financial markets.

Management will host a conference call and live webcast to discuss Evolus financial results at9:00 a.m. ET that same day. A question-and-answer session will follow managements remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of theEvoluswebsite at www.evolus.com.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international). An archived webcast can also be accessed on the Investor Relations page of theEvoluswebsite at www.evolus.com.

AboutEvolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure technology. Jeuveau is powered by Evolus unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us atwww.evolus.com.

Jeuveauis a registered trademark ofEvolus, Inc.

Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor/Media Contact:David K. Erickson, Evolus, Inc.Vice President, Investor RelationsTel: 949-966-1798Email: david.erickson@evolus.com